Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
For years, the pharmaceutical industry has measured R&D productivity at the wrong moment in time: FDA approval. However, approval is only one checkpoint. The harder questions come afterwards: Will payers cover this drug? Will patients start treatment? Will the investment ultimately pay off?
A new index from Norstella is reframing how the industry answers those questions. The Pipeline-to-Patient Productivity Index (P3i) is the first benchmarking tool that follows a molecule across its entire journey: from early disclosure through clinical development, into…
Market access teams spend a lot of time preparing for payer meetings, but they rarely know how well those meetings went. To answer that need, MMIT’s Message Monitor has been capturing unaided, immediate payer feedback on pharma meetings for the past 15 years, providing clients with qualitative and quantitative data.
Now, with the platform's new self-service interface and Ella AI querying tool, teams can explore the entire Message Monitor archive directly, asking the kinds of strategy questions that used to require…
Pharma companies are deploying AI tools across a broad range of market access functions, from payer account strategy to contracting and beyond. According to our 2026 State of Patient Access research, 65% say that AI and RWD are ‘very important’ or ‘mission-critical’ to their access models today.
We sat down with two MMIT experts, Liz Rolla and Carolyn Zele, for a candid conversation about what AI can actually do for market access teams, how it's changing the role of analysts, and…
Biosimilar adoption and vertical integration used to be separate challenges for manufacturers — one focused on formulary competition, the other on navigating payer consolidation. New Q2 2026 MMIT Indices research suggests they've merged into a single prevailing pressure.
As more payers fold PBMs, specialty pharmacies, and even physician practices into their own operations, the same consolidated entities now setting formulary strategy are also the ones deciding a biosimilar's fate. Manufacturers of biosimilars are no longer just competing against reference products. Instead,…
For years, immunology has ranked as one of the top therapeutic areas by value, with year-over-year growth driven by blockbuster biologics for conditions like rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). Now, a wave of therapies with novel mechanisms of action (MoAs) is expanding the immunology conditions that can be treated, even as biosimilars and Medicare price negotiation compress the value of legacy brands.
The top 20 immunology drugs generated roughly $81 billion in 2024, growing at nearly 9.4%…
Pharma manufacturers invest significant time and money developing resources for payers, from budget impact models to PIE packages and NCCN summaries. But are those resources hitting the mark?
New Q1 2026 MMIT Indices research, surveying commercial payers representing more than 126 million covered lives and Medicare plans representing 50 million lives, offers a few insights. The findings reveal not just what payers say they want, but where most manufacturer-provided materials still fall short.
On the clinical side, payers want detailed efficacy…
After years of record growth driven by subsidized premiums, enrollment in Affordable Care Act (ACA) exchange plans plummeted this year from its all-time high of 24.3 million members in 2025. Enrollment in Medicaid and commercial group risk plans is on the decline, while Medicare enrollment is more static; meanwhile, enrollment in commercial ASO/self-funded plans is on the upswing.
What do these shifts mean for providers, manufacturers, payers and health IT vendors? Let’s take a look at the data from MMIT’s Directory of…
Launching a new therapy is one of the most consequential moments in a pharmaceutical brand’s lifecycle. As we’ve said before, you only launch once! The difference between brands that achieve their uptake goals and those that fall short often comes down to one factor: how quickly can a team identify problems and adapt their strategy accordingly?
Many manufacturers enter a brand’s launch year with carefully developed forecasts, access assumptions, and adoption targets. Yet even the best plans can—and should—change in the…
Cell and gene therapies are no longer reserved only for ultra-rare diseases. In many therapeutic areas (TAs), advances in viral vector delivery, gene editing technologies, and cell-based medicine are enabling interventions that target disease at its biological source, often through a single administration rather than lifelong treatment.
These developments should be unequivocally positive for patients. However, as gene therapies transition from scientific breakthrough to commercial reality, a more complex picture of access is emerging. Insurance companies that were built to fund…
There is no doubt that payers in the U.S. are investing heavily in AI, but there is much uncertainty about how this technology is currently deployed. While the industry’s AI conversation has focused on generative tools and administrative efficiency, payers are increasingly deploying AI in utilization management, clinical pathways and contracting. According to research from MMIT’s Indices team, nearly half of payers are planning the implementation of at least one additional AI solution in the next 12–18 months.
Although AI-driven changes…
